Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
Stringer-Reasor E, Li Y, Witherspoon F, Specht J, Del Santo Anampa Mesias J, Nanda R, Dees E, Wolff A, Krop I, Lin N, Rimawi M, Yang E. Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050). Journal Of Clinical Oncology 2021, 39: tps1098-tps1098. DOI: 10.1200/jco.2021.39.15_suppl.tps1098.Peer-Reviewed Original ResearchHuman epidermal growth factor receptor 2Metastatic human epidermal growth factor receptor 2Dose-limiting toxicityBreast cancerResponse rateBC cellsEpidermal growth factor receptor 2Single-arm clinical trialECOG PS 0Efficacy of niraparibObjective response ratePhase 1b/2 studyGrowth factor receptor 2Arm clinical trialPARP inhibitor niraparibFactor receptor 2Poly (ADP-ribose) polymerase (PARP) inhibitorsNF-kB signalingMeasurable diseasePhase 1b/2Accrual goalEligible patientsPS 0Clinical benefitCNS disease